{"url_path":"/sec/pvct/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-022950-index.html","accession_number":"0001493152-26-022950","cik":"0000315545","ticker":"PVCT","issuer_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-022950-index.html","primary_entity_key":"0000315545","primary_entity_name":"PROVECTUS BIOPHARMACEUTICALS, INC."},"word_count":1205,"has_tables":true,"body_markdown":"false\nQ1\n--12-31\n0000315545\n\n0000315545\n\n2026-01-01\n2026-03-31\n\n0000315545\n\n2026-05-12\n\n0000315545\n\n2026-03-31\n\n0000315545\n\n2025-12-31\n\n0000315545\n\nus-gaap:NonrelatedPartyMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:NonrelatedPartyMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0000315545\n\nPVCT:SeriesDConvertiblePreferredStockMember\n\n2026-03-31\n\n0000315545\n\nPVCT:SeriesDConvertiblePreferredStockMember\n\n2025-12-31\n\n0000315545\n\nPVCT:SeriesDOneConvertiblePreferredStockMember\n\n2026-03-31\n\n0000315545\n\nPVCT:SeriesDOneConvertiblePreferredStockMember\n\n2025-12-31\n\n0000315545\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesDPreferredStockMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nPVCT:SeriesDOnePreferredStockMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:NoncontrollingInterestMember\n\n2025-12-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesDPreferredStockMember\n\n2024-12-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nPVCT:SeriesDOnePreferredStockMember\n\n2024-12-31\n\n0000315545\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0000315545\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0000315545\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2024-12-31\n\n0000315545\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0000315545\n\nus-gaap:NoncontrollingInterestMember\n\n2024-12-31\n\n0000315545\n\n2024-12-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesDPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nPVCT:SeriesDOnePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:NoncontrollingInterestMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesDPreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nPVCT:SeriesDOnePreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:NoncontrollingInterestMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesDPreferredStockMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nPVCT:SeriesDOnePreferredStockMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:NoncontrollingInterestMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nus-gaap:SeriesDPreferredStockMember\n\n2025-03-31\n\n0000315545\n\nus-gaap:PreferredStockMember\nPVCT:SeriesDOnePreferredStockMember\n\n2025-03-31\n\n0000315545\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0000315545\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0000315545\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-03-31\n\n0000315545\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0000315545\n\nus-gaap:NoncontrollingInterestMember\n\n2025-03-31\n\n0000315545\n\n2025-03-31\n\n0000315545\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:ConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:ConvertiblePreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyTwoUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyTwoUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFourUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFourUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveUnsecuredConvertibleNotesAndAccruedInterestMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneNoteMember\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nus-gaap:NonrelatedPartyMember\n\n2025-12-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nus-gaap:RelatedPartyMember\n\n2025-12-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneNoteMember\nus-gaap:RelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nus-gaap:NonrelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nus-gaap:RelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:NonrelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:RelatedPartyMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneNoteMember\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nus-gaap:NonrelatedPartyMember\n\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nus-gaap:RelatedPartyMember\n\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\n\n2025-01-15\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nPVCT:SeriesDOneConvertiblePreferredStockMember\n\n2025-01-15\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\nPVCT:OfficerAndDirectorMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveFinancingNoteMember\n\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneNoteMember\n\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneAndTwoThousandTwentyFiveNotesMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:TwoThousandTwentyOneToTwoThousandTwentyFiveNotesMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:ConvertibleNotesPayableMember\n\n2026-03-31\n\n0000315545\n\nus-gaap:ConvertibleNotesPayableMember\n\n2025-12-31\n\n0000315545\n\nPVCT:TwoThousandTwentyFiveNotesMember\nPVCT:SeriesDOneConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:ConsultantOptionsMember\n\n2025-04-01\n2025-04-01\n\n0000315545\n\nus-gaap:ResearchAndDevelopmentExpense\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:ResearchAndDevelopmentExpense\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:GeneralAndAdministrativeExpense\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nus-gaap:GeneralAndAdministrativeExpense\n\n2025-01-01\n2025-03-31\n\n0000315545\n\n2025-01-01\n2025-12-31\n\n0000315545\n\nPVCT:RangeOneMember\n\n2026-03-31\n\n0000315545\n\nPVCT:RangeOneMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:RangeTwoMember\n\n2026-03-31\n\n0000315545\n\nPVCT:RangeTwoMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:RangeThreeMember\n\n2026-03-31\n\n0000315545\n\nPVCT:RangeThreeMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:RangeFourMember\n\n2026-03-31\n\n0000315545\n\nPVCT:RangeFourMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nstpr:TN\n\n2026-03-31\n\n0000315545\n\nPVCT:VisiroseMember\n\n2026-03-31\n\n0000315545\n\nPVCT:VisiroseMember\n\n2025-03-31\n\n0000315545\n\nPVCT:VisiroseMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:VisiroseMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nPVCT:VisiroseMember\nPVCT:UniversityOfMiamiMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:VisiroseMember\nPVCT:UniversityOfMiamiMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nPVCT:VisiroseMember\nPVCT:UniversityOfMiamiMember\n\n2026-03-31\n\n0000315545\n\nPVCT:VisiroseMember\nPVCT:ProvectusMember\n\n2026-03-31\n\n0000315545\n\nPVCT:VisiroseMember\nPVCT:TwoInvestorsMember\n\n2026-03-31\n\n0000315545\n\nPVCT:ClinicalStageBiotechnologySegmentMember\n\n2026-01-01\n2026-03-31\n\n0000315545\n\nPVCT:ClinicalStageBiotechnologySegmentMember\n\n2025-01-01\n2025-03-31\n\n0000315545\n\nus-gaap:SubsequentEventMember\nPVCT:TwoThousandTwentyFiveNotesMember\n\n2026-05-14\n\n0000315545\n\nus-gaap:SubsequentEventMember\nPVCT:TwoThousandTwentyFiveNotesMember\n\n2026-04-01\n2026-05-14\n\n0000315545\n\nus-gaap:SubsequentEventMember\nPVCT:TwoThousandTwentyFiveNotesMember\nPVCT:SeriesDOnePreferredStockMember\n\n2026-04-01\n2026-05-14\n\n0000315545\n\nus-gaap:SubsequentEventMember\nPVCT:TwoThousandTwentyFiveNotesMember\nPVCT:SeriesDOnePreferredStockMember\n\n2026-05-14\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nutr:sqft\n\nPVCT:Australian\n\nPVCT:Segment\n\nxbrli:pure\n\n** **\n\n \n\n** **\n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n(Mark\nOne)\n\n \n\n☒\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor\nthe quarterly period ended March 31, 2026\n\n \n\nor\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from\n                      \nto                              **\n\n \n\n**Commission\nfile number 001-36457**\n\n \n\n**PROVECTUS\nBIOPHARMACEUTICALS, INC.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n \n\n**Delaware**\n \n**90-0031917**\n\n**(State\nor other jurisdiction**\n\n**of\nincorporation or organization)**\n\n \n\n**(I.R.S.\nEmployer**\n\n**Identification\nNo.)**\n\n \n \n \n\n**800\nS. Gay Street, Suite 1610**\n\n**Knoxville,\nTennessee**\n\n \n**37929**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\nCode)**\n\n \n\n**866-594-5999**\n\n**(Registrant’s\ntelephone number, including area code)**\n\n \n\n**Not\nApplicable**\n\n**(Former\nname, former address, and former fiscal year, if changed since last report)**\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\n \nTrading\nSymbol(s)\n \nName\nof each exchange on which registered\n\nNone\n\n \nN/A\n\n \nN/A\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). ☒ Yes ☐ No\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer\n☐\nAccelerated\nfiler\n☐\n\nNon-accelerated\nfiler\n☒\nSmaller\nreporting company\n☒\n\n \n \nEmerging\ngrowth company\n☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No\n\n \n\nThe\nnumber of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of May 12, 2026 was 420,279,879.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**TABLE\nOF CONTENTS**\n\n \n\n \nPage\n\n**PART I - FINANCIAL INFORMATION**\n \n\n \n \n\n[Cautionary Note Regarding Forward-Looking Statements](#sq_001)\n1\n\n[Item 1. Financial Statements (unaudited)](#sq_003)\n2\n\n[Condensed Consolidated Balance Sheets](#sq_004)\n2\n\n[Condensed Consolidated Statements of Operations](#sq_005)\n3\n\n[Condensed Consolidated Statements of Comprehensive Loss](#sq_006)\n4\n\n[Condensed Consolidated Statements of Changes in Stockholders’ Deficit](#sq_007)\n5\n\n[Condensed Consolidated Statements of Cash Flows](#sq_009)\n7\n\n[Notes to Condensed Consolidated Financial Statements](#sq_010)\n8\n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#wg_001)\n17\n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#wg_002)\n25\n\n[Item 4. Controls and Procedures](#wg_003)\n25\n\n \n \n\n**PART II - OTHER INFORMATION**\n \n\n \n \n\n[Item 1. Legal Proceedings](#wg_005)\n26\n\n[Item 1A. Risk Factors](#wg_006)\n26\n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#wg_007)\n26\n\n[Item 3. Defaults Upon Senior Securities](#wg_008)\n26\n\n[Item 4. Mine Safety Disclosures](#wg_009)\n26\n\n[Item 5. Other Information](#wg_010)\n26\n\n[Item 6. Exhibits](#wg_011)\n27\n\n \n \n\n**SIGNATURES**\n28\n\n \n\n \n\n \n\n \n\n**Cautionary\nNote Regarding Forward-Looking Statements**\n\n \n\nThis\nQuarterly Report on Form 10-Q contains “forward-looking statements” as defined under U.S. federal securities laws. These\nstatements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations. These statements also express\nmanagement’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,”\n“believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,”\n“plan,” “predict,” “project,” “should,” “strategy,” “will,” and\nother similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results\nto materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking\nstatements. Such statements are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such\nstatements after this date, unless otherwise required by law.\n\n \n\nRisks\nand uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include\nthose discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”) (including those described in"}